Key Publications
Oliveira NAS, Pinho BR, Oliveira JMA* (2023). Swimming against ALS: how to model disease in zebrafish for pathophysiological and behavioral studies. Neuroscience and Biobehavioral Reviews 148:105138 - https://doi.org/10.1016/j.neubiorev.2023.105138
Silva RFO, Pinho BR, Santos MM, Oliveira JMA* (2022) Disruptions of circadian rhythms, sleep, and stress responses in zebrafish: new infrared-based activity monitoring assays for toxicity assessment. Chemosphere 305:135449 - https://doi.org/10.1016/j.chemosphere.2022.135449
Almeida LM, Pinho BR, Duchen MR, Oliveira JMA* (2022) The PERKs of mitochondria protection during stress: insights for PERK modulation in neurodegenerative and metabolic diseases. Biological Reviews 97:1737-1748 - https://doi.org/10.1111/brv.12860
Silva RFO, Pinho BR, Monteiro NM, Santos MM, Oliveira JMA* (2022) Automated analysis of activity, sleep, and rhythmic behaviour in various animal species with the Rtivity software. Scientific Reports, 12:4179 https://www.nature.com/articles/s41598-022-08195-z | Link to software
Pinho BR, Almeida LM, Duchen MR, Oliveira JMA* (2021) Allosteric activation of Hsp70 reduces mutant huntingtin levels, the clustering of N-terminal fragments, and their nuclear accumulation. Life Sciences, 285:120009 https://doi.org/10.1016/j.lfs.2021.120009
Pinho BR, Duarte AI, Canas PM, Moreira P, Murphy MP, Oliveira JMA* (2020) The interplay between redox signalling and proteostasis in neurodegeneration: In vivo effects of a mitochondria-targeted antioxidant in Huntington’s disease mice. Free Radical Biology and Medicine, 146:372-382
Soares TR, Reis SD, Pinho BR, Duchen MR, Oliveira JMA* (2019) Targeting the proteostasis network in Huntington's disease. Ageing Research Reviews 49:92-103
Pinho BR, Reis SD, Hartley RC, Murphy MP, Oliveira JMA* (2019) Mitochondrial superoxide generation induces a parkinsonian phenotype in zebrafish and huntingtin aggregation in human cells. Free Radical Biology and Medicine, 130:318-327
Reis SD, Pinho BR, Oliveira JMA* (2017) Modulation of molecular chaperones in Huntington’s disease and other polyglutamine disorders. Molecular Neurobiology, 54:5829-5854
Pinho BR, Reis SD, Guedes-Dias P, Leitão-Rocha A, Quintas C, Valentão P, Andrade PB. Santos MM, Oliveira JMA* (2016) Pharmacological modulation of HDAC1 and HDAC6 in vivo in a zebrafish model: therapeutic implications for Parkinson's disease. Pharmacological Research, 103:328-339
Guedes-Dias P, Pinho BR, Soares TR, de Proenca J, Leitao-Rocha A, Duchen MR, Oliveira JMA* (2016) Mitochondrial dynamics and quality control in Huntington's disease. Neurobiology of Disease, 90:51-7
Guedes-Dias P, de Proenca J, Soares TR, Leitao-Rocha A, Pinho BR, Duchen MR, Oliveira JMA* (2015) HDAC6 inhibition induces mitochondrial fusion, autophagic flux and reduces diffuse mutant huntingtin in striatal neurons. BBA Molecular Basis of Disease, 1852:2484-2493
Leitão-Rocha A, Guedes-Dias P, Pinho BR, Oliveira JMA* (2015) Trends in mitochondrial therapeutics for neurological disease. Current Medicinal Chemistry, 22(20): 2458-2467
Almalki AA, Alston CL, Parker A, Simonic I, Mehta SG, He L, Reza M, Oliveira JMA, Lightowlers RN, McFarland R, Taylor RW, Chrzanowska-Lightowlers ZMA (2014) Mutation of the human mitochondrial phenylalanine-tRNA synthetase causes infantile-onset epilepsy and cytochrome c oxidase deficiency. BBA Molecular Basis of Disease, 1842:56-64
Guedes-Dias P, Oliveira JMA* (2013) Lysine deacetylases and mitochondrial dynamics in neurodegeneration. BBA Molecular Basis of Disease, 1832:1345-1359
Bruni F, Gramegna P, Oliveira JMA, Lightowlers RN, Chrzanowska-Lightowlers ZMA (2013) REXO2 Is an Oligoribonuclease Active in Human Mitochondria. PLoS ONE, 8(5): e64670. doi:10.1371/journal.pone.0064670
Pinho BR, Santos MM, Fonseca-Silva A, Valentão P, Andrade PB, Oliveira JMA* (2013) How mitocondrial dysfunction affects zebrafish development and cardiovascular function: An in vivo model for testing mitochondria-targeted drugs. British Journal of Pharmacology, 169:1072-1090
Oliveira JMA* (2011) Techniques to investigate neuronal mitochondrial function and its pharmacological modulation. Current Drug Targets, 12, 762-773
Oliveira JMA & Lightowlers RN (2010) Could successful (mitochondrial) networking help prevent Huntington's disease? EMBO Molecular Medicine, 2:487-489
Oliveira JMA* (2010) Nature and cause of mitochondrial dysfunction in Huntington's Disease: Focusing on huntingtin and the striatum. Journal of Neurochemistry, 114:1-12
Oliveira JMA* (2010) Mitochondrial bioenergetics and dynamics in Huntington’s disease: tripartite synapses and selective striatal degeneration. Journal of Bioenergetics and Biomembranes, 42:227-34
Oliveira JMA* & Gonçalves J (2009) In situ mitochondrial Ca2+ buffering differences of intact neurons and astrocytes from cortex and striatum. Journal of Biological Chemistry, 284(8): 5010-5020
Canas PM, Porciúncula LO, Cunha GM, Silva C, Machado N, Oliveira JMA, Oliveira CR, Cunha RA (2009) Adenosine A2A receptor blockade prevents synaptotoxicity and memory dysfunction caused by beta-amyloid peptides via P38 MAP Kinase pathway. Journal of Neuroscience, 29(47):14741-14751
Oliveira JMA, Jekabsons MB, Chen S, Lin A, Rego AC, Gonçalves J, Ellerby LM and Nicholls DG (2007) Mitochondrial dysfunction in Huntington’s disease: the bioenergetics of isolated and in situ mitochondria from transgenic mice. Journal of Neurochemistry, 101: 241-249
Oliveira JMA, Chen S, Almeida S, Riley R, Gonçalves J, Oliveira CR, Hayden MR, Nicholls DG, Ellerby LM and Rego AC (2006) Mitochondrial-dependent Ca2+ handling in Huntington’s disease striatal cells: Effect of HDAC inhibitors. Journal of Neuroscience, 26(43):11174-11186
